Casdin Capital
Leading life sciences and healthcare investment firm focused on growth-stage investments. Known for significant positions in genomics and precision medicine companies. Long-term, thesis-driven investor in transformative healthcare.
Website
https://casdincapital.comLocation
New York, USA
Founded
2011
AUM
$3B+
Investment Range
$25M - $150M
Portfolio Companies
3
Focus
biotech-focused
Fund Stages
series-c, growth
Investment Thesis
Casdin Capital focuses on growth-stage investments in life sciences and healthcare companies at the intersection of technology and biology. They take concentrated, long-term positions in companies with transformative potential in genomics, precision medicine, and healthcare technology.
Team
Partners / Managing Directors (Health & Bio Focus)
- Eli Casdin - Founder & Chief Investment Officer
- Aaron Schwartz - Managing Director
- Caroline Popper, PhD - Managing Director
Other Key Team Members
- Investment team with deep healthcare and life sciences expertise
Focus Areas
- Genomics
- Precision Medicine
- Life Science Tools
- Diagnostics
- Healthcare Technology
- Digital Health
- Growth Stage Biotech
Notable Exits
- Grail - Acquired (2021, by Illumina for $8B)
- Guardant Health - IPO (2018, NASDAQ: GH) - liquid biopsy
- 10x Genomics - IPO (2019, NASDAQ: TXG)
- Natera - Growth investor (NASDAQ: NTRA)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| 10x Genomics | Pleasanton, California, USA | 2012 | genomics-sequencingbiotech+1 |
| Foundation Medicine | Cambridge, Massachusetts, USA | 2010 | genomics-sequencingdiagnostics+3 |
| Treeline Biosciences | Cambridge, Massachusetts, USA | 2022 | therapeuticsbiotech+3 |